Literature DB >> 2592769

IL-2 protects T cell hybrids from the cytolytic effect of glucocorticoids. Synergistic effect of IL-2 and dexamethasone in the induction of high-affinity IL-2 receptors.

E Fernández-Ruiz1, A Rebollo, M A Nieto, E Sanz, C Somoza, F Ramirez, A Lopez-Rivas, A Silva.   

Abstract

IL-2-independent CD8+ rat x BW5147 T cell hybridomas are highly sensitive to treatment with 10(-6) M dexamethasone. This glucocorticoid analog induces a rapid DNA fragmentation with a pattern similar to that observed during glucocorticoid-induced killing of mouse thymocytes, which suggests the activation of a similar specific endonuclease. Among these hybrids, we select variants expressing low affinity IL-2R, as measured by IL-2 binding assay and by the cell surface expression of the IL-2Rp55 Ag (rat CD25 recognized by OX-39 mAb). These OX-39+ IL-2 independent hybrids (named V type) are protected from the toxic action of dexamethasone by IL-2. The addition of IL-2 to V type cells induces the expression of a low number of high affinity IL-2R, which is strongly potentiated by the simultaneous addition of dexamethasone. Furthermore, dexamethasone is strongly synergistic with IL-2 in the induction of mRNA p55/IL-2R, which could be observed 6 h after the treatment. These data suggest that the utilization of the IL-2-R signaling pathway may induce an effective protection against glucocorticoid toxicity in mature T cells. Finally, we proved that the upregulation of IL-2R by IL-2 is strongly potentiated by glucocorticoids, which implies a new role for these agents in the immune system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2592769

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  A novel mechanism of glucocorticoid-induced immune suppression: the inhibiton of T cell-mediated terminal maturation of a murine dendritic cell line.

Authors:  T Kitajima; K Ariizumi; P R Bergstresser; A Takashima
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 2.  Mechanisms of cell death.

Authors:  D J Fawthrop; A R Boobis; D S Davies
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

3.  Glucocorticoids enhance concanavalin A-induced mitogenic response through the inhibition of nitric oxide production.

Authors:  F Ramírez; A Silva
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 4.  Glucocorticoids and central nervous system inflammation.

Authors:  Klaus Dinkel; William O Ogle; Robert M Sapolsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 5.  CD8+ Tc2 cells: underappreciated contributors to severe asthma.

Authors:  Timothy S C Hinks; Ryan D Hoyle; Erwin W Gelfand
Journal:  Eur Respir Rev       Date:  2019-11-20

Review 6.  Spectrum of T-lymphocyte activities regulating allergic lung inflammation.

Authors:  Erwin W Gelfand; Anthony Joetham; Meiqin Wang; Katsuyuki Takeda; Michaela Schedel
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

7.  Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.

Authors:  Christian S Hinrichs; Douglas C Palmer; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2005 Nov-Dec       Impact factor: 4.456

8.  A role for the intermediate affinity IL-2R in the protection against glucocorticoid-induced apoptosis.

Authors:  A Rebollo; C Pitton; A García; J Gómez; A Silva
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

9.  Dexamethasone up-regulates granulocyte-macrophage colony-stimulating factor receptor expression on human monocytes.

Authors:  C M Hawrylowicz; L Guida; E Paleolog
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

10.  Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes.

Authors:  L Lanza; M Scudeletti; F Puppo; O Bosco; L Peirano; G Filaci; E Fecarotta; G Vidali; F Indiveri
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.